News | March 30, 2022
Sun Pharma gets exclusive patent licence for Vortioxetine
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The product is expected to be available in a week’s time
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Subscribe To Our Newsletter & Stay Updated
